Developments in Glioblastoma-Specific Molecular Treatment

In terms of incidence, recurrence rate, and biological activity, glioblastoma, abbreviated as GB, is the most prevalent kind of high-grade intracranial malignant tumor [1]. Approximately 0.59-3.69 per 100,000 people are diagnosed with GBM with a median onset age of 63.0 years, making up 15.4% of all primary brain tumors and 45.6% of all malignant brain tumors every year. Males have age-adjusted morbidity of 3.97, while females have a morbidity of 2.53 per 100,000. GBMs impact roughly 1500 people in Italy each year, whereas in the United States, 12,120 instances of GBM were identified [2, 3].